Cyclization of dipeptidyl chloromethyl ketones gave 6-(4-aminobutyl)-3-carboxyethyl-5-methyl-2(1H)-pyrazinone, 3-(4-aminobutyl)-6-carboxyethyl-5-methyl-2(1H)-pyrazinone, and 3,6-bis(4-aminobutyl)-5-methyl-2(1H)-pyrazinone, which were inserted into the enkephalin sequence to give opioid mimetics. Thus, it was confirmed that a pyrazinone ring can be easily inserted into a peptide sequence in order to evaluate structural components required for biologically active peptides.
Previously, an easy and convenient synthetic procedure for the preparation of 2(1H)-pyrazinone derivatives from dipeptidyl chloromethyl ketones was developed.
2) This novel method afforded 2(1H)-pyrazinone derivatives substituted with the desired functional groups at the 3 and 6 positions in high yield. Therefore, an amino and/or a carboxyl group can be easily introduced at position 3 or 6 of the pyrazinone ring by using appropriate amino acids.
3) It was also reported that 5-methyl-6-b -phenethyl-3-tyrosylaminobutyl-2-(1H)-pyrazinone exhibited fairly potent binding activity to the m-opioid receptor with a K i value of 55.8 nM and to a d-opioid receptor with a K i value of 2165 nM and a K i m/K i d value of 0.026, while 5-methyl-3-benzyl-6-tyrosylaminobutyl-2-(1H)-pyrazinone exhibited weak affinity for the d-opioid receptor with a K i value of 332.7 nM, and for the m-opioid receptor with a K i value of 3909 nM and K i m/K i d value of 11.7.
4) The above two compounds exhibited different binding activity profiles. One notable difference in structure between the above two compounds is the orientation of the carbonyl groups on the pyrazinione ring. The position of the carbonyl may be an important factor for m-opioid receptor interaction. 4) Therefore, in order to introduce conformational restrictions in the biologically active opioid-peptide enkephalin, three pyrazinonering containing compounds (1, 2, 3) were considered, as shown in Fig. 1 . Using these templates, we designed opioid mimetics I and II, in which pyrazinone fragments were substituted for Gly 2 and Gly 3 in the enkephalin sequence 5) and Leu 5 was deleted as shown in Fig. 2 . We synthesized I and II and examined their opioid receptor binding activities. The synthesis and opioid receptor-binding activity of compound III (Fig. 2) will also be described.
The desired opioid mimetics (I and II) were prepared according to Chart 1. Two types of amino acids containing a pyrazinone ring (1 and 2) were prepared starting from Boc-Glu(OBzl)-Lys(Z)-CH 2 Cl and Boc-Lys(Z)-Glu(OBzl)-CH 2 Cl, respectively. The amino group was protected with a Fmoc group by using Fmoc-OSu to give compounds (4 and 5). Fmoc amino acids (4 and 5) were coupled with H-Phe-OBu t by BOP reagent to give dipeptides (6 and 7, respectively). After removal of the Fmoc group, the resultant dipeptide amine was coupled with Boc-Tyr-OH by BOP reagent to give protected tripeptides (8 and 9, respectively). Fig. 3 . Compounds I and II exhibited opioid receptor-binding activity with K i d of 1610 nM and 1040 nM, and K i m of 3120 nM and 4080 nM, respectively. These peptide mimetics contained functional groups known to be important for opioid receptor interaction; namely the hydroxyl group on tyrosine, the N-terminal amine and the presence of two aromatic groups.
6) Yet both compounds were inactive in the radiolabeled ligand-binding assay. Since both compounds were inactive, it could be surmised that the distance between the two aromatic rings was too large to manifest opioid receptor August 1999 Communications to the Editor 9) Com-pound III exhibited quite a different opioid receptor-binding activity profile compared with Tyr 4 -enkeplalin and a cystamine-enkephalin dimer. Therefore, it can be deduced that this result exhibits the possibility that compound III acts at different m-opioid receptors.
In conclusion, the pyrazinone platform serves as a template for developing diverse opioid peptides that may prove useful for clinical and therapeutic applications, and compound III is a candidate of a lead compound for developing m-receptor agonists and antagonists.
